JP2022545387A5 - - Google Patents

Info

Publication number
JP2022545387A5
JP2022545387A5 JP2022509196A JP2022509196A JP2022545387A5 JP 2022545387 A5 JP2022545387 A5 JP 2022545387A5 JP 2022509196 A JP2022509196 A JP 2022509196A JP 2022509196 A JP2022509196 A JP 2022509196A JP 2022545387 A5 JP2022545387 A5 JP 2022545387A5
Authority
JP
Japan
Prior art keywords
patient
entrectinib
administration
grade
severity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022509196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046229 external-priority patent/WO2021030619A1/en
Publication of JP2022545387A publication Critical patent/JP2022545387A/ja
Publication of JP2022545387A5 publication Critical patent/JP2022545387A5/ja
Pending legal-status Critical Current

Links

JP2022509196A 2019-08-14 2020-08-13 がんの処置方法 Pending JP2022545387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886948P 2019-08-14 2019-08-14
US62/886,948 2019-08-14
PCT/US2020/046229 WO2021030619A1 (en) 2019-08-14 2020-08-13 Methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2022545387A JP2022545387A (ja) 2022-10-27
JP2022545387A5 true JP2022545387A5 (enExample) 2023-08-18

Family

ID=72266851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022509196A Pending JP2022545387A (ja) 2019-08-14 2020-08-13 がんの処置方法

Country Status (6)

Country Link
US (1) US20220257592A1 (enExample)
EP (1) EP4013404A1 (enExample)
JP (1) JP2022545387A (enExample)
CN (1) CN114222576A (enExample)
TW (1) TW202114676A (enExample)
WO (1) WO2021030619A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230454A1 (en) * 2022-05-24 2023-11-30 Icahn School Of Medicine At Mount Sinai Neurotrophic tyrosine receptor kinase inhibitors as therapeutics for liver disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299057B2 (en) 2007-07-20 2012-10-30 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
KR20230169457A (ko) * 2017-01-27 2023-12-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법

Similar Documents

Publication Publication Date Title
Lee Intracerebral hemorrhage
BR112021015129A2 (pt) Método para tratar um paciente que sofre de hipercortisolemia e um sintoma ou comorbidade da mesma
EP2891499A1 (en) Combination of sglt2 inhibitor and anti-hypertension drug
EP4164624A1 (en) Methods for treating or preventing chronic kidney disease
JP5745526B2 (ja) 糖尿病の予防のためのスルホンアミド
WO2021238957A1 (zh) 法米替尼在制备用于治疗c-KIT或PDGFRA突变的肿瘤的药物中的用途
Bonvini et al. Sinus arrest and moderate hyperkalemia
KR20170125927A (ko) 골밀도의 조절 방법
Ellis et al. Bell's palsy in an older patient with uncontrolled hypertension due to medication nonadherence
TW202440099A (zh) 治療胃腸道基質瘤方法
Zhong et al. Positive inotropic drugs and drugs used in dysrhythmias
Guo Acute allograft renal failure with marked hyperuricemia developing during mizoribine administration: a case report with review of the literature
Thaper et al. Progression of ECG in hydroxychloroquine overdose
McNierney et al. SUN-915 diffuse large B cell lymphoma presents with femur fracture and involvement of thyroid gland
CN113226374B (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
Azizi et al. Resistant Hypertension
Valentino et al. Digoxin toxicity caused by an interaction with the novel hepatitis C medication ledipasvir/sofosbuvir
WO2025256469A1 (zh) 一种药物组合物及其应用
Mahfoud et al. RENAL DENERVATION IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION: 5A. 02
CN116648445A (zh) 治疗或预防慢性肾脏病的方法
WO2025056075A1 (zh) 一种用于逆转苄异喹啉类肌松药的肌松拮抗药物
CN120284970A (zh) Cb-839在制备治疗糖尿病肾脏病药物中的应用
Nozaki et al. Results of unilateral adrenalectomy in subclinical C ushing's syndrome due to adrenocorticotropic hormone‐independent macronodular adrenal hyperplasia
Jaejin et al. CARDIOVASCULAR OUTCOMES AND ALL-CAUSE MORTALITY ASSOCIATED WITH APPARENT TREATMENT-RESISTANT HYPERTENSION APPLYING THE 2017 ACC/AHA GUIDELINE
CA3241884A1 (en) Levonorgestrel butanoate formulation and methods relating thereto